Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novartis Ag ADR (NY: NVS )

102.90 +0.06 (+0.06%)
Streaming Delayed Price Updated: 12:38 PM EDT, May 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Novartis Ag ADR

< Previous 1 2
...
20 21 22 23 24 25 26 27 Next >
Novartis' Neuroendocrine Tumors Targeted Radiotherapy Takes Small Hit on Clinically Relevant Overall Survival
Novartis AG (NYSE: NVS) reported the final analysis from the NETTER-1 phase 3 study comparing Lutathera plus 30 mg Sandostatin LAR (octreotide) to 60 mg octreotide... 
Via Benzinga
The Daily Biotech Pulse: Merck, AstraZeneca, Novartis Among Early Presenters At ASCO, Sanofi Strikes Breast Cancer Study Pact
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 3) BioCryst Pharmaceuticals,... 
Via Benzinga
Fan Hit
The 10-yr US treasury yield rose to 1.6% again. Later in the day, a rally was attempted, mostly for the meme shares. 
Via Talk Markets
Novartis' Prostate Cancer Radioligand Therapy Extended Overall Survival by Four Months
Novartis AG (NYSE: NVS) has announced results from Phase 3 VISION study evaluating 177Lu-PSMA-617, a targeted radioligand therapy, plus best standard of care (SOC... 
Via Benzinga
This Genetics Stock Could Have a Bright Future
Here's one genetics play that you might want to put on your radar. 
Via The Motley Fool
The Daily Biotech Pulse: FDA Nod For Novartis, iRhythm CEO Quits Abruptly, Moderna Inks Vaccine Supply Agreements
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 1) Anika Therapeutics, Inc. (... 
Via Benzinga
Exposures Product Safety
Novartis's Late-stage Study On Cosentyx Hits Primary Endpoint Goal In Juvenile Idiopathic Arthritis
Novartis AG (NYSE: NVS) said that the Phase 3 JUNIPERA study met its primary endpoint, with Cosentyx (secukinumab) showing a significantly longer time to worsening of... 
Via Benzinga
Novartis's Cosentyx Wins FDA Approval For Psoriasis In Pediatric Patients
The FDA has approved Novartis AG’s (NYSE: NVS) Cosentyx (secukinumab) to treat moderate to severe plaque psoriasis in pediatric patients six years and older... 
Via Benzinga
Exposures Product Safety
A Catch-Up Day
OPEC had a virtual meeting about rising demand for oil and rising demand that oil companies cut their carbon footprint. 
Via Talk Markets
Novartis Terminates Three Beovu Studies in Ocular Disorders Citing Patient Safety
Novartis AG (NYSE: NVS) has announced that three Phase 3 studies evaluating Beovu (brolucizumab) in patients with retinal diseases will be terminated early after... 
Via Benzinga
More Inflationary Pressures
Today, we saw more evidence of worrying inflationary pressures from the personal consumption index hitting 3.1% in April over prior April, up sharply from the March rise of 1.9%. 
Via Talk Markets
New New Deal Worries
Nio is up 1.4% today on another round of Meme buying. 
Via Talk Markets
Artificial Intelligence Doctor App Ada Health Closes $90M Funding Led By Bayer, Samsung
German digital health firm Ada Health has raised a $90 million funding round at an undisclosed valuation bringing total investment in the company up to around $150... 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Novartis, Molecular Partners Initiate Global Trial For COVID-19 Treatment
Novartis AG (NYSE: NVS) along with Molecular Partners AG (OTC: MLLCF) is kicking off a Phase 2/3 EMPATHY study of DARPin therapeutic candidate, ensovibep (... 
Via Benzinga
Exposures COVID-19
Worldwide Upbeat
The US crackdown on cryptocurrencies continues with the Fed today indicating that an official crypto-currency is going to be created for the USA. 
Via Talk Markets
Topics Economy
Exposures Interest Rates
The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes On Long-Term Migraine Drug Data, Decision Day For Eton, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 26) I-Mab (NASDAQ: IMAB)... 
Via Benzinga
Exposures COVID-19
How Small Biotech Allogene Is Making Waves For Gilead, Novartis
Allogene Therapeutics said its donor cell-derived cancer treatment was successful for six months, and ALLO stock popped Thursday. 
Via Investor's Business Daily
Who Runs The Best-Performing Company You've Never Heard Of?
Entegris is a top company and big winner for investors. Why haven't more people heard of it? Entegris CEO Bertrand Loy chuckles when he hears the question. 
Via Investor's Business Daily
The Daily Biotech Pulse: Pfizer In Vaccine Supply Talks With India, Provention In Focus Ahead Of Briefing Doc, NeuroRx To List Via SPAC Deal
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 24) Bristol-Myers Squibb Company... 
Via Benzinga
Cathie Wood Buys Another $39M Tesla Shares On Dip, Also Adds Bitcoin Plays Square, Coinbase
Cathie Wood-led Ark Investment Management on Wednesday snapped up 69,508 shares, worth about $39.2 million, in Tesla Inc (NASDAQ: 
Via Benzinga
Cathie Wood's Ark Loads Up Further On Tesla And Cuts Apple Stake
Cathie Wood-led Ark Investment Management on Tuesday snapped up $27.2 million worth of shares in Tesla Inc (NASDAQ: TSLA) after a two-week gap during which shares of the... 
Via Benzinga
Supreme Court Rebuffs Novartis Appeal Over Amgen's Arthritis Drug Enbrel: Report
The Supreme Court turned away a petition from Sandoz seeking to challenge two Amgen Inc (NASDAQ: AMGN) patents related to rheumatoid arthritis drug Enbrel,... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Novartis' Entresto Misses Primary Endpoint In Study After Heart Attacks
Novartis AG (NYSE: NVS) revealed details on Phase 3 PARADISE-MI trial evaluating Entresto (sacubitril/valsartan) compared with ramipril in a contemporary... 
Via Benzinga
Cathie Wood Cuts Apple Stake Almost Entirely — And Buys More Coinbase
Cathie Wood-led Ark Investment Management on Monday shed nearly all of its stake in Apple Inc (NASDAQ: 
Via Benzinga
15 European Dividend Aristocrats To Diversify Your Portfolio
In general, Dividend Aristocrats are the foundation for the portfolios of most serious dividend growth investors. European Dividend aristocrats are typically blue chip stocks that... 
Via Benzinga
Cathie Wood Sheds $33.6M Alibaba Shares On Earnings Day
Cathie Wood-led Ark Investment Management on Thursday shed 162,840 shares, worth about $33.6 million, in Alibaba Group Holding (NYSE: BABA) after the company posted its first... 
Via Benzinga
Gold Up Four Days In A Row
The dollar is at a nearly 3 month low. 
Via Talk Markets
Cathie Wood Piles Up Palantir For Third Day In A Row, Adding $39M Worth Of Shares
Cathie Wood-led Ark Investment Management on Wednesday snapped up 2.07 million shares, worth about $39 million, in Palantir Technologies Inc (NYSE: PLTR), on a day the... 
Via Benzinga
Cathie Wood Loads Up Another $28M Worth Of Shares In Alibaba Rival JD.Com
Cathie Wood-led Ark Investment Management on Friday bought 366,879 shares, worth about $27.7 million, in JD.com Inc (NASDAQ: JD), a key rival to Alibaba Group Holding (NYSE: BABA... 
Via Benzinga
Cathie Wood Loads Up $57M In Palantir As Stock Stages Reversal On Q1 Earnings Beat
Cathie Wood-led Ark Investment Management on Tuesday snapped up 2.8 million shares, worth about $56.7 million, in Palantir Technologies Inc (NYSE: PLTR) after the data analytics... 
Via Benzinga
< Previous 1 2
...
20 21 22 23 24 25 26 27 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.